Vitiligo (Investigational)

Patient Summary

Is this FDA-cleared for this use?

Not FDA-cleared for vitiligo. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for vitiligo is highly investigational.

What evidence exists?

Tier C (highly investigational). Only anecdotal case reports describe limited repigmentation; there are no randomized controlled trials. Evidence-based options per AAD 2023 guideline include topical calcineurin inhibitors (tacrolimus 0.1 percent), topical ruxolitinib cream (FDA-approved 2022 for nonsegmental vitiligo), topical corticosteroids, narrow-band UVB phototherapy (the most effective non-surgical option), excimer laser, and surgical melanocyte transplantation for stable limited disease. Vitiligo is autoimmune; peripheral leech application is unlikely to address that pathophysiology.

Main risks

• Bleeding from bite sites for 6 to 24 hours after detachment
• Koebner phenomenon — new vitiligo patches at bite sites (this is the dominant risk in vitiligo)
• Bruising and tenderness for 5 to 10 days
• Local skin infection or, rarely, Aeromonas infection
• Allergic reaction to leech saliva (uncommon)
• Post-inflammatory hyperpigmentation or hypopigmentation at bite sites
• Permanent scars at bite sites
• Delay or replacement of effective therapy with risk of disease progression

Who should not consider this

• Patients with active progressive vitiligo (new patches in the last 6 months — needs stabilization first)
• Patients with a documented Koebnerization tendency
• Patients with segmental vitiligo (different mechanism — consider melanocyte transplant)
• Patients on topical ruxolitinib (drug interaction unknown)
• Patients with skin malignancy or atypical nevi at proposed sites
• Patients on anticoagulants, with hemophilia, or with severe anemia

What to ask your clinician

• Has my vitiligo been stable for at least 6 months with no new lesions?
• Have I tried topical tacrolimus or topical ruxolitinib (Opzelura) — the only FDA-approved nonsegmental vitiligo therapy?
• Have I been offered narrow-band UVB phototherapy or excimer laser?
• Am I a candidate for surgical melanocyte transplantation for stable patches?
• What is my Koebnerization risk, and how does it impact leech therapy decisions?
• What is the realistic effect size with leech therapy versus proven options?
• What is the practitioner's experience and Aeromonas-prevention plan?

When to seek urgent care

• Rapidly progressive new vitiligo patches (suggests active autoimmune flare)
• Spreading redness, warmth, pus, or red streaks (cellulitis)
• Bleeding from a bite site lasting more than 24 to 48 hours
• New vitiligo at the bite site itself (Koebner phenomenon)
• Fever above 38.0 C / 100.4 F or chills
• Hives, throat tightness, or breathing difficulty